Our discovery of the interaction between NRF1 and the OGT/HCF-1 complex has added a new regulatory axis to the proteasome bounce-back response and identified OGT as a new therapeutic target for sensitizing cancer cells to proteasome inhibitors. The gene discussed is NRF1; the disease is cancer.